Comparison of Tramadol vs Remifentanyl Patient Controlled Analgesia for Second Trimester Abortions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00361686|
Recruitment Status : Completed
First Posted : August 8, 2006
Last Update Posted : November 24, 2015
Patients undergoing second trimester abortions will recieve either patient controlled analgesia with either remifentanyl or tramadol for pain alleviation.
We beleive both to be equally effective for pain alleviation.
|Condition or disease||Intervention/treatment||Phase|
|Abortion,Induced||Drug: tramadol Drug: remifentanyl Device: patient contolled analgesia||Not Applicable|
Women undergoing second trimester abortions will recieve patient controlled analgesia eith either tramadol or remifentanyl.
Patients will not know what they are recieving.
Patients in the tramadol goup will get a loading dose of tramadol and metocloparamide while the women in the remifentanyl group will be given a loading placebo.
Women will then be attached to one of the two patinet controlled analgesia protocols.
Throughout their laboring process they will be monitored for blood pressure, pulse, breathing rate, sedation score and nausea.
Additional medicatyion will be given for nausea.
If woman are still in pain the patient controlled analgesia settings will be set to deliver a higher dose. If the woman remains in pain, she will be given an additional per os medication.If this still does not alleviate pain, the option of epidural analgesia will be offered.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Randomized Double Blind Study Comparing Patient Controlled Analgesia With Tramadol vs. Remifentanyl for Women Undergoing 2nd Trimester Abortions|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||January 2007|
|Actual Study Completion Date :||January 2007|
- VAS scores
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00361686
|Rabin Medical Center|
|Petach Tiqvah, Israel|
|Study Director:||Sharon Orbach-Zinger||Rabin Medical Center|